English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A. Gerakis, Department of Medicine, Division of, Nephrology,’Evagelismos’ Hospital, Athens (Greece) Dear Sir, Aluminum seems to exert its detrimental effect on bone formation mainly by decreasing the number and activity of the osteo-blasts [1]. Osteocalcin (bone Gla protein, BGP) is the main noncollagenous protein of bone matrix and it is synthesized exclusively by osteoblasts. A small fraction of this unique protein circulates in serum, where it is easily determined, reflecting accurately the osteoblastic activity [2]. Surprisingly, the effect of desferrioxam-ine (DFO) administration and subsequent Al removal on BGP values has not been investigated till now in dialyzed patients with Al toxicity, except for one report by Davie et al. [3] recently published in Nephron. According to this report an ‘anomalous rise of serum osteocalcin’ was observed in a concervatively treated patient with chronic renal failure after a short course of DFO therapy. Therefore, we studied BGP changes in 10 patients with a mean age of 56 ± 18 years, treated by hemodialysis (6 patients) or CAPD (4 patients) for 44 ± 32 months who received DFO for 9.5 ± 2.5 months. All patients were submitted to bone biopsy before and after the DFO treatment. The initial bone biopsies showed, besides Al bone deposition, secondary hyperparathyroidism in 3 patients, mixed bone disease in 5 patients and osteomalacia and aplastic bone disease in 1 patient each. BGP was determined by two methods: first by conventional radioimmunoassay (RIA) which measures, besides intact BGP, its fragments as well; and second, by a new two-site immunoradiometric assay (IRMA) which measured only intact BGP. Given that BGP fragments derive both from degradation of intact BGP and from bone resorption, it is believed that BGP measured by RIA reflects not only osteoblastic activity but bone resorption as well, whereas BGP measured by IRMA reflects only osteoblastic activity. After DFO treatment, bone biopsies revealed that Al removal had been achieved in 8 patients. However, osteoblastic activity was not significantly affected by DFO treatment, since histomorphometric indices of osteoblastic activity (i.e. osteoblast surface and bone formation rate) remained virtually unchanged. Moreover, BGP values measured by IRMA during DFO treatment remained stable at around 300 ng/ml. In contrast, BGP values measured by RIA showed a sixfold increase (from 32 to 189 ng/ml, p < 0.001) during the first 2 months and subsequently dropped to values twice higher compared to the initial ones. This abrupt rise in BGP which, to our knowledge, has not been described till now in the literature was ascribed to osteocalcin fragments which were measured by RIA,

Release of Osteocalcin Fragments in the Serum of Dialyzed Patients during Desferrioxamine Treatment